Jan 22 |
15 Small-Cap Stocks with High Potential
|
Jan 8 |
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
|
Jan 3 |
Olema Pharmaceuticals: Oral SERD Developer With Interesting Data
|
Jan 2 |
Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
|
Dec 19 |
$6.9M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
|
Dec 11 |
Insiders Buying Walt Disney And 3 Other Stocks
|
Dec 5 |
Olema posts Phase 1/2 data for lead asset in breast cancer
|
Dec 5 |
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
|
Dec 1 |
Top Stocks for December 2023
|
Nov 28 |
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
|